ArticleCNS drugs2018

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Marita Zimmermann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.